Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy

Takaaki Suzuki, Hitomi Koga, Shingo Yamazaki, Hiromi Saeki, Hiroaki Tanaka, Miki Nishimura, Chiaki Nakaseko, Hiromitsu Nakasa, Hiroyoshi Nakamura, Noritaka Ariyoshi, Mitsukazu Kitada

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The pharmacologic effects of warfarin might be altered by various factors, including drug-drug interaction. Case summary: A 49-year-oold Japanese man (height, 174 cm; weight, 68 kg) presented with a 20-month history of malignant lymphoma (diffuse large B cell lymphoma, clinical stage IV). He was treated with a combination of rituximab chemotherapy and etoposide, cisplatin, high-dose cytarabine, and methyl-prednisolone (R-ESHAP). He had been receiving warfarin for the secondary prevention of pulmonary embolism with deep venous thrombosis. When R-ESHAP was started, international normalized ratio (INR) increased from 1 to 5. This phenomenon was observed again in the second R-ESHAP. The INR was increased from 2.44 to 4.71 during chemotherapy but was returned to within the normal range (1.05; normal range: 0.81-1.009) 5 days after chemotherapy was completed. Conclusion: In this patient, R-ESHAP chemotherapy might have affected warfarin anticoagulation sensitivity; thus, careful monitoring of INR is essential, particularly in patients receiving warfarin who underg go R-ESHAP chemotherapy.

Original languageEnglish
Pages (from-to)1155-1159
Number of pages5
JournalClinical Therapeutics
Volume30
Issue number6
DOIs
Publication statusPublished - Jun 2008
Externally publishedYes

Fingerprint

Warfarin
Antineoplastic Agents
International Normalized Ratio
Drug Therapy
Reference Values
Lymphoma, Large B-Cell, Diffuse
Cytarabine
Etoposide
Secondary Prevention
Prednisolone
Combination Drug Therapy
Pulmonary Embolism
Drug Interactions
Venous Thrombosis
Cisplatin
Lymphoma
Weights and Measures
Pharmaceutical Preparations

Keywords

  • cisp platin
  • etoposide
  • interaction
  • warfarin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Suzuki, T., Koga, H., Yamazaki, S., Saeki, H., Tanaka, H., Nishimura, M., ... Kitada, M. (2008). Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy. Clinical Therapeutics, 30(6), 1155-1159. https://doi.org/10.1016/j.clinthera.2008.06.008

Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy. / Suzuki, Takaaki; Koga, Hitomi; Yamazaki, Shingo; Saeki, Hiromi; Tanaka, Hiroaki; Nishimura, Miki; Nakaseko, Chiaki; Nakasa, Hiromitsu; Nakamura, Hiroyoshi; Ariyoshi, Noritaka; Kitada, Mitsukazu.

In: Clinical Therapeutics, Vol. 30, No. 6, 06.2008, p. 1155-1159.

Research output: Contribution to journalArticle

Suzuki, T, Koga, H, Yamazaki, S, Saeki, H, Tanaka, H, Nishimura, M, Nakaseko, C, Nakasa, H, Nakamura, H, Ariyoshi, N & Kitada, M 2008, 'Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy', Clinical Therapeutics, vol. 30, no. 6, pp. 1155-1159. https://doi.org/10.1016/j.clinthera.2008.06.008
Suzuki, Takaaki ; Koga, Hitomi ; Yamazaki, Shingo ; Saeki, Hiromi ; Tanaka, Hiroaki ; Nishimura, Miki ; Nakaseko, Chiaki ; Nakasa, Hiromitsu ; Nakamura, Hiroyoshi ; Ariyoshi, Noritaka ; Kitada, Mitsukazu. / Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy. In: Clinical Therapeutics. 2008 ; Vol. 30, No. 6. pp. 1155-1159.
@article{8d5bc75a9cab4fe1995c71307a6ec9d4,
title = "Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy",
abstract = "Background: The pharmacologic effects of warfarin might be altered by various factors, including drug-drug interaction. Case summary: A 49-year-oold Japanese man (height, 174 cm; weight, 68 kg) presented with a 20-month history of malignant lymphoma (diffuse large B cell lymphoma, clinical stage IV). He was treated with a combination of rituximab chemotherapy and etoposide, cisplatin, high-dose cytarabine, and methyl-prednisolone (R-ESHAP). He had been receiving warfarin for the secondary prevention of pulmonary embolism with deep venous thrombosis. When R-ESHAP was started, international normalized ratio (INR) increased from 1 to 5. This phenomenon was observed again in the second R-ESHAP. The INR was increased from 2.44 to 4.71 during chemotherapy but was returned to within the normal range (1.05; normal range: 0.81-1.009) 5 days after chemotherapy was completed. Conclusion: In this patient, R-ESHAP chemotherapy might have affected warfarin anticoagulation sensitivity; thus, careful monitoring of INR is essential, particularly in patients receiving warfarin who underg go R-ESHAP chemotherapy.",
keywords = "cisp platin, etoposide, interaction, warfarin",
author = "Takaaki Suzuki and Hitomi Koga and Shingo Yamazaki and Hiromi Saeki and Hiroaki Tanaka and Miki Nishimura and Chiaki Nakaseko and Hiromitsu Nakasa and Hiroyoshi Nakamura and Noritaka Ariyoshi and Mitsukazu Kitada",
year = "2008",
month = "6",
doi = "10.1016/j.clinthera.2008.06.008",
language = "English",
volume = "30",
pages = "1155--1159",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy

AU - Suzuki, Takaaki

AU - Koga, Hitomi

AU - Yamazaki, Shingo

AU - Saeki, Hiromi

AU - Tanaka, Hiroaki

AU - Nishimura, Miki

AU - Nakaseko, Chiaki

AU - Nakasa, Hiromitsu

AU - Nakamura, Hiroyoshi

AU - Ariyoshi, Noritaka

AU - Kitada, Mitsukazu

PY - 2008/6

Y1 - 2008/6

N2 - Background: The pharmacologic effects of warfarin might be altered by various factors, including drug-drug interaction. Case summary: A 49-year-oold Japanese man (height, 174 cm; weight, 68 kg) presented with a 20-month history of malignant lymphoma (diffuse large B cell lymphoma, clinical stage IV). He was treated with a combination of rituximab chemotherapy and etoposide, cisplatin, high-dose cytarabine, and methyl-prednisolone (R-ESHAP). He had been receiving warfarin for the secondary prevention of pulmonary embolism with deep venous thrombosis. When R-ESHAP was started, international normalized ratio (INR) increased from 1 to 5. This phenomenon was observed again in the second R-ESHAP. The INR was increased from 2.44 to 4.71 during chemotherapy but was returned to within the normal range (1.05; normal range: 0.81-1.009) 5 days after chemotherapy was completed. Conclusion: In this patient, R-ESHAP chemotherapy might have affected warfarin anticoagulation sensitivity; thus, careful monitoring of INR is essential, particularly in patients receiving warfarin who underg go R-ESHAP chemotherapy.

AB - Background: The pharmacologic effects of warfarin might be altered by various factors, including drug-drug interaction. Case summary: A 49-year-oold Japanese man (height, 174 cm; weight, 68 kg) presented with a 20-month history of malignant lymphoma (diffuse large B cell lymphoma, clinical stage IV). He was treated with a combination of rituximab chemotherapy and etoposide, cisplatin, high-dose cytarabine, and methyl-prednisolone (R-ESHAP). He had been receiving warfarin for the secondary prevention of pulmonary embolism with deep venous thrombosis. When R-ESHAP was started, international normalized ratio (INR) increased from 1 to 5. This phenomenon was observed again in the second R-ESHAP. The INR was increased from 2.44 to 4.71 during chemotherapy but was returned to within the normal range (1.05; normal range: 0.81-1.009) 5 days after chemotherapy was completed. Conclusion: In this patient, R-ESHAP chemotherapy might have affected warfarin anticoagulation sensitivity; thus, careful monitoring of INR is essential, particularly in patients receiving warfarin who underg go R-ESHAP chemotherapy.

KW - cisp platin

KW - etoposide

KW - interaction

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=47149101829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47149101829&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2008.06.008

DO - 10.1016/j.clinthera.2008.06.008

M3 - Article

VL - 30

SP - 1155

EP - 1159

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -